[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-arterial-disease-pad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-arterial-disease-pad":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100638631","personalizing-thromboprophylaxis-for-patients-with-peripheral-artery-disease-100638631",false,"NCT07613840","Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease","Personalizing Post Surgical Thromboprophylaxis for Patients With Peripheral Artery Disease","Inclusion Criteria:\n\n* Patients with a named arterial extremity injury or named vessel revascularization for atherosclerosis requiring open and\u002For closed revascularization.\n* Patients at the age of 18 or older\n\nExclusion Criteria:\n\n* Patients who are younger than 18 years old\n* Known pregnancy (females of childbearing potential will have a pregnancy test prior to surgery as per standard of care)\n* Prisoners, defined as those who have been directly admitted from a correctional facility.\n* No atherosclerosis\n* Subject has active stomach ulcers\n* Subject has severe hepatic impairment\n* Subject has a recent history of intracranial hemorrhage. If the patient has a history of cerebral hemorrhage with no new central nervous system disease of \\>1 year, the study team will consult with the","ALL","18 Years",{"count":19,"type":20},484,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore blood flow to their legs.\n\nThe main questions it aims to answer are:\n\n* Does the personalized plan lower the rate of blood clots in the treated leg one year after the procedure?\n* Does the personalized plan lower rates of amputation, repeat procedures, bleeding, and death compared to standard treatment?\n\nResearchers will compare the personalized TARGET plan which uses a blood test to tailor each person's blood clot prevention medication to the standard treatment to see if the personalized approach works better.\n\nParticipants will:\n\n* Be randomly assigned to either the personalized TARGET plan or standard treatment after their procedure\n* Have blood tests at 1 week and at 1, 3, 6, 9, and 12 months after their procedure\n* Have medications adjusted based on blood test results if assigned to the TARGET group",[26,27,28,29,30,31,32],"Peripheral Arterial Disease (PAD)","Amputation","Thrombosis","Thrombosis (Stent Thrombosis)","Platelet Aggregation Inhibitors","Thromboelastography (TEG)","PRU(Platelet Reactivity Unit)",[34,35,36,37,38,39],"Peripheral Artery Disease Thromboprophylaxis","Personalizing Blood Thinners","Clopidogrel Resistance","Thromboelastography with Platelet Mapping (TEG-PM)","Graft\u002F Stent Thrombosis","Platelet Inhibition","RECRUITING","2026-05-21",{"date":43,"type":44},"2026-05-29","ACTUAL",{"date":46,"type":44},"2025-04-29",{"date":48,"type":20},"2027-06-30",{"name":50,"class":51},"Massachusetts General Hospital","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":21,"phases":65,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100640487","recreational-team-handball-programme-for-patients-with-peripheral-arterial-disease-100640487","NCT07582588","Recreational Team Handball Programme for Patients With Peripheral Arterial Disease","RUSH (Rehabilitation Using Sequential Handball): Promoting Health in Patients With Peripheral Arterial Disease With Intermittent Claudication Through a Progressive Recreational Team Handball-based Programme","Inclusion Criteria:\n\n* 60-80-year-old males\n* Diagnosed with stage II LEPAD secondary to arteriosclerosis\n* Ankle-brachial index \\\u003C 0.90 in one or both lower limbs\n* With or without former revascularization surgery\n* With medical clearance from the physician to perform moderate-to-vigorous intensity exercise\n\nExclusion Criteria:\n\n* Diagnosed with stage I, III or IV LEPAD\n* Advanced retinopathy or kidney failure\n* Incapability to grab a ball\n* Other cardiovascular disease (heart failure, atrial fibrillation, valvular heart disease, unstable angina or other uncontrolled arrhythmias, obstructive coronary disease, acquired or advance heart block)\n* Diabetic neuropathy\n* Foot ulcers\n* Uncontrolled hypertension\n* History of major depression or other severe psychiatric disorders\n* Cancer\n* Severe hepatic impairment\n* Previous amputation surgery\n* Adherence to regular physical activity or exercise (\\>2 hours and half per week) in the last 6 months","MALE","60 Years","80 Years",{"count":64,"type":20},60,[23],"This randomized controlled trial (RCT) aims to evaluate the physical and physiological demands, the feasibility and the health, physical fitness and disease-specific outcomes of a progressive recreational team handball-based programme in patients with lower extremity peripheral arterial disease and intermittent claudication. The primary outcomes will be changes in functional capacity, assessed by the 6-minute walk test. Participants will be randomized to either a 24-week progressive team handball-based intervention or a usual care control group, with assessments performed at baseline, 12 weeks, and 24 weeks post intervention to evaluate health, physical fitness, and disease- specific outcomes.",[26],[69,70,71,72],"Exercise rehabilitation","Peripheral arterial disease","Intermittent claudication","Walking sports","NOT_YET_RECRUITING","2026-05-11",{"date":76,"type":44},"2026-05-13",{"date":78,"type":20},"2026-05-14",{"date":80,"type":20},"2027-07-01",{"name":82,"class":51},"University Institute of Maia",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":83},"100619091","expression-of-glp1-receptor-on-peripheral-blood-mononuclear-cells-in-advanced-peripheral-artery-disease-paving-the-way-for-glp1r-agonists-treatment-in-chronic-limb-threatening-ischemia-100619091","NCT07340112","Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening Ischemia","EXCEL-CLTI","Inclusion Criteria:\n\n* Patients aged 40 years or older\n* Documented Peripheral Artery Disease (PAD): Patients must fall into one of the two following severity groups:\n\n  1. Intermittent Claudication (IC) Group: Defined by a maximum walking distance limited by intermittent claudication, associated with an Ankle-Brachial Index (ABI) \\\u003C 0.9 at rest.\n  2. Chronic Limb-Threatening Ischemia (CLTI) Group: Defined by ischemic rest pain and\u002For tissue loss (ulcers or gangrene) persisting for at least 15 days, associated with a toe pressure or a transcutaneous oxygen tension (tcPO2) \\\u003C 30 mmHg, according to the 2024 ESC guidelines.\n\nExclusion Criteria:\n\n* Diabetes Mellitus: Diagnosis of Type 1 or Type 2 diabetes\n* Current Specific Pharmacotherapy: Ongoing treatment with SGLT2 inhibitors (SGLT2i) or GLP-1 receptor agonists (GLP-1RA).\n* Infection: Presence of sepsis or an active systemic infection.\n* Malignancy: Active cancer or hematologic malignancies.\n* Immunosuppression: History of organ transplantation or autoimmune diseases currently requiring immunosuppressive therapy.\n* Known chronic inflammatory diseases.\n* Advanced Renal Failure: End-stage renal disease requiring dialysis.","40 Years",{"count":93,"type":20},50,"OBSERVATIONAL","The goal of this observational study is to learn whether activation of the GLP-1 receptor could represent a therapeutic target by characterizing its expression and associated inflammatory mechanisms in patients with peripheral artery disease, according to disease severity, in adults with symptomatic lower-limb peripheral arterial disease.\n\nThe main questions it aims to answer are:\n\n* Is the level of GLP-1 receptor (GLP1R) expression on peripheral blood mononuclear cells (PBMC) different between patients with intermittent claudication (ischemia of effort) and those with chronic limb-threatening ischemia?\n* Is GLP1R expression associated with inflammatory and oxidative profiles of PBMC?\n* Can GLP-1 receptor agonists reverse inflammatory and oxidative alterations induced by plasma from patients with peripheral artery disease in endothelial cell cultures?\n* Are there specific plasma proteomic signatures associated with GLP1R overexpression?\n\nResearchers will compare patients with intermittent claudication to patients with chronic limb-threatening ischemia to see if disease severity is associated with differences in GLP1R expression, PBMC inflammatory\u002Foxidative phenotype, and plasma proteomic profiles.\n\nParticipants will:\n\n* Provide an additional blood sample (15 mL) collected during a routine, clinically indicated blood draw\n* Have PBMC isolated for measurement of GLP1R expression and assessment of inflammatory and oxidative markers\n* Have plasma analyzed for proteomic profiling and used in in-vitro endothelial cell experiments\n\nParticipation ends after completion of the blood sampling, and no additional procedures beyond standard clinical care are required.",[26,97,98],"Claudication, Intermittent","Chronic Limb-Threatening Ischemia",[70,100,101,102],"Chronic limb-threatening ischemia","GLP-1 receptor","Peripheral blood mononuclear cells (PBMC)","2026-01-05",{"date":105,"type":44},"2026-01-14",{"date":107,"type":20},"2026-06",{"date":109,"type":20},"2028-06",{"name":111,"class":51},"University Hospital, Strasbourg, France"]